# A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer

> **NCT05621434** · PHASE2 · UNKNOWN · sponsor: **Fujian Medical University** · enrollment: 63 (estimated)

## Conditions studied

- HER2-positive Recurrent/Metastatic Breast Cancer

## Interventions

- **DRUG:** Inetetamab, pyrotinib, chemotherapy

## Key facts

- **NCT ID:** NCT05621434
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-10
- **Primary completion:** 2024-12-10
- **Final completion:** 2025-12-10
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2022-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05621434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05621434, "A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05621434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*